AU769294B2 - Pyrrolidincarbonylamino cyclic disulfides - Google Patents

Pyrrolidincarbonylamino cyclic disulfides Download PDF

Info

Publication number
AU769294B2
AU769294B2 AU47482/00A AU4748200A AU769294B2 AU 769294 B2 AU769294 B2 AU 769294B2 AU 47482/00 A AU47482/00 A AU 47482/00A AU 4748200 A AU4748200 A AU 4748200A AU 769294 B2 AU769294 B2 AU 769294B2
Authority
AU
Australia
Prior art keywords
compound
amino
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47482/00A
Other languages
English (en)
Other versions
AU4748200A (en
Inventor
Li Chen
Nader Fotouhi
David Young Jackson
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU4748200A publication Critical patent/AU4748200A/en
Application granted granted Critical
Publication of AU769294B2 publication Critical patent/AU769294B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU47482/00A 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides Ceased AU769294B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US60/130215 1999-04-20
PCT/EP2000/003459 WO2000063234A2 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists

Publications (2)

Publication Number Publication Date
AU4748200A AU4748200A (en) 2000-11-02
AU769294B2 true AU769294B2 (en) 2004-01-22

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47482/00A Ceased AU769294B2 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides

Country Status (15)

Country Link
US (1) US6265572B1 (https=)
EP (1) EP1171452B1 (https=)
JP (1) JP2002542256A (https=)
KR (1) KR100636481B1 (https=)
CN (1) CN1167710C (https=)
AR (1) AR023546A1 (https=)
AT (1) ATE337331T1 (https=)
AU (1) AU769294B2 (https=)
BR (1) BR0009838A (https=)
CA (1) CA2370259A1 (https=)
DE (1) DE60030266T2 (https=)
ES (1) ES2269141T3 (https=)
TR (1) TR200103004T2 (https=)
WO (1) WO2000063234A2 (https=)
ZA (1) ZA200108018B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
CA2598816A1 (en) * 2005-02-28 2006-08-31 Medichem S.A. Process and methods for the preparation of gabapentin and its intermediates
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2850885A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
BR0009838A (pt) 2002-01-08
EP1171452B1 (en) 2006-08-23
AR023546A1 (es) 2002-09-04
KR20010108517A (ko) 2001-12-07
AU4748200A (en) 2000-11-02
WO2000063234A3 (en) 2001-01-18
CA2370259A1 (en) 2000-10-26
US6265572B1 (en) 2001-07-24
EP1171452A2 (en) 2002-01-16
DE60030266T2 (de) 2007-07-19
TR200103004T2 (tr) 2002-01-21
ES2269141T3 (es) 2007-04-01
ATE337331T1 (de) 2006-09-15
DE60030266D1 (de) 2006-10-05
WO2000063234A2 (en) 2000-10-26
ZA200108018B (en) 2003-03-26
CN1347419A (zh) 2002-05-01
CN1167710C (zh) 2004-09-22
JP2002542256A (ja) 2002-12-10
KR100636481B1 (ko) 2006-10-18

Similar Documents

Publication Publication Date Title
US5719296A (en) Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
RU2266901C2 (ru) 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
US6630492B1 (en) Lymphocyte function antigen-1 antagonists
AU625456B2 (en) Diol-containing renin inhibitors
JP3727536B2 (ja) Ｎ−アルカノイルフェニルアラニン誘導体
AU769294B2 (en) Pyrrolidincarbonylamino cyclic disulfides
SK49194A3 (en) Urethanes and ureas which are inducing production of cytokine
EP0618223A2 (en) Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents
LT3626B (en) Compounds containing a fused bicycle ring and processing thereof
SA98190557A (ar) مشتقات n- أرويل فينيل ألانين.
AU642046B2 (en) N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
JP6333267B2 (ja) アザインドリン
KR20150065718A (ko) 인돌린
NZ226395A (en) Renin-inhibiting amino acid derivatives and pharmaceutical compositions
JPS60136595A (ja) 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤
JPH06199820A (ja) 三環及び四環式化合物
EP0745081B1 (en) indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
US7767645B2 (en) SH2 domain binding inhibitors
MXPA01010543A (en) Pyrrolidincarbonylamino cyclic disulfides
JP4659843B2 (ja) ホスフィニックアミノ酸（ｐｈｏｓｐｈｉｎｉｃａｍｉｎｏａｃｉｄｓ）の新規な誘導体、その製造方法およびそれを含有する医薬組成物
MXPA00001743A (es) Derivados de n-alcanoilfenilalanina
MXPA01008376A (en) Thioamide derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)